|1.||Newhall, K: 1 article (12/2008)|
|2.||Shannon, H E: 1 article (12/2008)|
|3.||Peters, S C: 1 article (12/2008)|
|4.||Territo, P R: 1 article (12/2008)|
|5.||Rodewald, J M: 1 article (12/2008)|
|6.||Burnett, T J: 1 article (12/2008)|
|7.||Engleking, D R: 1 article (12/2008)|
|8.||Bin, T: 1 article (12/2008)|
|9.||Abdul-Karim, B: 1 article (12/2008)|
|10.||Freise, K J: 1 article (12/2008)|
07/01/1991 - "Ameltolide, a novel anticonvulsant agent, has been shown in animal models to be effective in controlling seizures. "
12/01/2008 - "Plasma ameltolide concentrations were determined at the time of seizures in all dogs and complete plasma concentration-time profiles were also determined in a separate study. "
12/01/2008 - "Eight dogs were administered five different oral doses of ameltolide and clinical scoring of the maximal electroshock (MES) induced seizures at 3 and 24 h postdosing were determined in two separate crossover design studies. "
03/01/1988 - "Compound ADD 75073 was ineffective in nontoxic doses against all other seizure models examined in this study, and thus has a pharmacologic profile similar to that of PHT."
12/01/2008 - "The fitted model estimated that from 2 to 15 h following a single 3 mg/kg oral ameltolide dose the mean probability of obtaining a 1 unit reduction in the seizure clinical score severity was greater than 0.80. "
|2.||Sodium Channels (Sodium Channel)
|3.||Serotonin (5 Hydroxytryptamine)
|8.||Anticonvulsants (Antiepileptic Drugs)